Phase III Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer: a Multicentre, Open-label, Randomised Study

Trial Profile

Phase III Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer: a Multicentre, Open-label, Randomised Study

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Aug 2016 Status changed from recruiting to completed.
    • 23 Sep 2013 Planned number of patients changed from 208 to 224 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top